ADVFN Logo ADVFN

We could not find any results for:
Make sure your spelling is correct or try broadening your search.

Trending Now

Toplists

It looks like you aren't logged in.
Click the button below to log in and view your recent history.

Hot Features

Registration Strip Icon for alerts Register for real-time alerts, custom portfolio, and market movers

EOLS Evolus Inc

13.30
0.08 (0.61%)
03 May 2024 - Closed
Delayed by 15 minutes
Share Name Share Symbol Market Type
Evolus Inc NASDAQ:EOLS NASDAQ Common Stock
  Price Change % Change Share Price Bid Price Offer Price High Price Low Price Open Price Shares Traded Last Trade
  0.08 0.61% 13.30 11.65 13.90 13.54 13.20 13.40 1,126,051 23:52:51

Evolus to Present at the Cantor Global Healthcare Conference

20/09/2018 9:01pm

GlobeNewswire Inc.


Evolus (NASDAQ:EOLS)
Historical Stock Chart


From May 2019 to May 2024

Click Here for more Evolus Charts.

Evolus, Inc. (NASDAQ:EOLS), a company dedicated to aesthetic medicine, announced today that members of management will present at the Cantor Global Healthcare Conference in New York, NY.

 Event:Cantor Global Healthcare Conference
 Date:Monday, October 1, 2018
 Time:8:55 AM ET
 Location:Intercontinental New York Barclay Hotel, New York, NY

A live audio webcast of the event can be accessed on the Events & Presentations page of the Investors section of Evolus’s website at http://www.evolus.com, or by following the link below in your web browser. An archived replay of the webcast will be available on Evolus’s website for 30 days after the live event concludes.

Webcast Link: http://wsw.com/webcast/cantor7/eols/ 

About Evolus, Inc.

Evolus is a company dedicated to aesthetic medicine focused on providing physicians and their patients with expanded choices in aesthetic treatments and procedures. Evolus’ lead candidate DWP-450, also known by the chemical name prabotulinumtoxinA, is a 900 kDa purified botulinum toxin type A complex that was approved by Health Canada for the temporary improvement in the appearance of moderate to severe glabellar lines in adult patients under 65 years of age and is being evaluated for marketing approval in the United States and other areas.

Evolus Contacts:

Investor Contacts:Ashwin Agarwal, EvolusTel: +1-949-284-4559Email: IR@Evolus.com

Brian Johnston, The Ruth Group Tel: +1 646-536-7028Email: IR@Evolus.com

Media Contact:Kirsten Thomas, The Ruth GroupTel: +1-508-280-6592Email: kthomas@theruthgroup.com 

1 Year Evolus Chart

1 Year Evolus Chart

1 Month Evolus Chart

1 Month Evolus Chart

Your Recent History

Delayed Upgrade Clock